drugset
drugset / Trial / NCT01429740

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

NCT01429740 ↗

Phase 1 Completed 29 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.

Timeline

Start
2011-08
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05180999 Small molecule 0.1 mg Oral
Subject PF-05180999 Small molecule 0.3 mg Oral
Subject PF-05180999 Small molecule 1 mg Oral
Subject PF-05180999 Small molecule 3 mg Oral
Subject PF-05180999 Small molecule 10 mg Oral
Subject PF-05180999 Small molecule 30 mg Oral
Subject PF-05180999 Small molecule 100 mg Oral
Subject PF-05180999 Small molecule 250 mg Oral

Indications

schizophrenia